Johnson & Johnson (JNJ) Stake Decreased by Brightworth
Brightworth trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,205 shares of the company’s stock after selling 186 shares during the quarter. Johnson & Johnson accounts for 0.2% of Brightworth’s portfolio, making the stock its 24th largest position. Brightworth’s holdings in Johnson & Johnson were worth $292,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Street Corp lifted its position in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. Korea Investment CORP lifted its position in Johnson & Johnson by 38.9% in the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after acquiring an additional 596,134 shares in the last quarter. Bank of Nova Scotia lifted its position in Johnson & Johnson by 94.5% in the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Johnson & Johnson in the 1st quarter valued at $65,598,000. Finally, CIBC World Markets Inc. lifted its position in Johnson & Johnson by 111.8% in the 1st quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock valued at $118,155,000 after acquiring an additional 500,662 shares in the last quarter. 66.00% of the stock is currently owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) traded up 1.49% on Monday, hitting $132.93. 2,469,541 shares of the stock traded hands. The stock has a 50 day moving average of $132.39 and a 200 day moving average of $128.88. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The firm has a market capitalization of $356.78 billion, a PE ratio of 22.49 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.74 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Stake Decreased by Brightworth” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/11/johnson-johnson-jnj-stake-decreased-by-brightworth.html.
Several equities research analysts recently commented on JNJ shares. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Cowen and Company set a $147.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, August 24th. UBS AG reaffirmed a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research report on Thursday, August 31st. BidaskClub cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $140.00 price objective on shares of Johnson & Johnson in a research report on Friday, June 16th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and an average target price of $134.60.
In related news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.